
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech has demonstrated a robust pipeline with positive initial data from its Phase 2 studies, particularly regarding Ampligen's application in both post-COVID conditions and as part of a chemokine modulatory regimen for metastatic colorectal cancer. These results not only validate the efficacy of Ampligen but also position the company favorably within the immuno-pharmaceutical market, addressing significant unmet medical needs. Furthermore, the continual release of strong positive data is expected to serve as a catalyst for potential stock growth as investor confidence is bolstered by these developments.
Bears say
AIM ImmunoTech reported a net loss of $3.3 million, with earnings per share (EPS) of $(1.57), significantly underperforming both the company’s and consensus estimates. The firm's ongoing financial challenges are compounded by a reliance on the success of its product candidates, with risks including potential failures in clinical trials, regulatory approvals, and commercialization efforts. Additionally, external factors such as liquidity risks, competition, and shifting investor sentiment towards biotech stocks heighten the uncertainty surrounding AIM ImmunoTech's financial outlook.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares